Ovagen

Ovagen — Liver Bioregulator

Ovagen is a Khavinson-class short-chain bioregulator peptide that restores youthful gene expression in liver tissue.

Peptide Specifications

Parameter	Value
Sequence	Lys-Glu-Asp
Mass	390.4 g/mol
Purity	>98.0%
Target Organ	Liver

Figure 1: Ovagen Organ-Specific Bioregulation

Tissue-Specific Mechanism

1. Hepatotropic tripeptide targeting liver parenchymal cells.
2. Restores gene expression damaged by chronic toxic or fatty liver.
3. Normalizes Phase I/II detoxification enzyme cascades.
4. Regenerates damaged liver lobule architecture.
5. Reduces hepatic fibrosis by downregulating stellate cell activation.

Figure 2: Liver Regeneration Curve

Research Results

• 1: Khavinson peptide for liver tissue regeneration.
• 2: Studied for reversing NAFLD biomarkers.
• 3: Provides deep hepatoprotection against future damage.

Hepatic & Gastrointestinal Bioregulator

Ovagen (Glu-Asp-Leu) is a synthetic tripeptide bioregulator derived from liver tissue, targeting hepatocyte and gastrointestinal epithelial cell gene expression. It restores age-related decline in liver detoxification capacity, bile synthesis, protein production, and gastrointestinal mucosal integrity. The liver’s central role in metabolism means that age-related hepatocyte dysfunction cascades into systemic effects: impaired drug metabolism, dyslipidemia, reduced albumin synthesis, and compromised bile acid homeostasis. Ovagen addresses these at the transcriptional level.

1. Ovagen tripeptides enter hepatocyte nuclei and modulate chromatin accessibility at promoter regions of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2D6).
2. Phase I and Phase II detoxification gene expression is normalized, restoring the liver’s capacity to metabolize drugs, toxins, and endogenous waste products.
3. Albumin synthesis gene expression is upregulated, improving plasma oncotic pressure and carrier protein availability.
4. Bile acid synthesis enzymes (CYP7A1, CYP27A1) are normalized, restoring cholesterol catabolism and fat-soluble vitamin absorption.
5. In GI epithelium, Ovagen promotes mucosal barrier gene expression (tight junction proteins, mucin glycoproteins), improving intestinal integrity.

Liver & GI Research Applications

• Hepatoprotection: In toxic liver injury models (CCl4, alcohol), Ovagen pretreatment reduced ALT/AST elevations and histological damage scores, indicating preserved hepatocyte function.
• Aging Liver: Age-related decline in CYP450 enzyme activity (responsible for the increased drug sensitivity in elderly patients) is partially reversed by Ovagen course administration.
• Lipid Metabolism: Normalization of hepatic lipid handling enzymes contributes to improved lipid profiles in hyperlipidemia research models.
• GI Integrity: The dual hepatic/GI activity makes Ovagen relevant for gut-liver axis research, where intestinal barrier dysfunction drives hepatic inflammation.
• Protocol: 1–2 capsules daily for 20–30 days. Often combined with Svetinorm (another liver bioregulator) for comprehensive hepatic support.